Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NVP-2002** is an oral fixed-dose antidiabetic combination product developed by NVP Healthcare that contains **linagliptin** and **metformin**. Linagliptin inhibits dipeptidyl peptidase-4, prolonging endogenous incretin activity and supporting glucose-dependent insulin secretion, while metformin primarily lowers hepatic glucose production and improves insulin sensitivity. NVP-2002 was evaluated in a completed Phase 1 pharmacokinetic and safety study in healthy adults against co-administration of its individual component products, NVP-2002-R1 and NVP-2002-R2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NVP-2002.